English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

It was shown that Tacrolimus (TAC) can suppress inflammation and immune response involved in liver ischemic reperfusion injury (IRI) (Kristo I., Transpl Int. 2011). The aim: We hypothesize that back-table arterial and portal liver perfusion with TAC can influence the incidence and severity of EAD. A prospective randomized study was conducted (ClinicalTrials.gov Identifier: NCT01887171). Materials and methods: Including criteria: 1 liver transplantation from DBD donor with sequential portal-arterial reperfusion. At back-table portal vein and hepatic artery were perfused each by 500 ml of HTK solution containing 20 ng/ml TAC during 10-15 min followed by portal flushing with 200 ml 5% solution of Albumin containing 20 ng/ml TAC and by resting of liver in effluent. No Tac was added in the control group. Primary Outcome: EAD (Olthoff KM, et al. Liver Transpl. 2010) and severe EAD (P.R. Salvalaggio, et al. Transpl.

Portal and Arterial Flushing with HTK and Tacrolimus Can Attenuate the Incidence of Early Liver Allograft Dysfunction